Gamma Knife Perfexion System Supplied By American Shared Hospital Services Begins Treating Patients At Florence Nightingale Hospital Group In Istanbul, Turkey
AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading
provider of turnkey technology solutions for advanced radiosurgical and
radiation therapy services, announced today that the Gamma Knife®
AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that the Gamma Knife® Perfexion™ system it supplied to Florence Nightingale Hospital Group in Istanbul through its EWRS Turkey subsidiary has begun treating patients. AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D., said, "This is the thirteenth Perfexion installation made possible by AMS' flexible financing solutions, and our first outside the United States. This Perfexion is in addition to the Gamma Knife and linear accelerator we previously supplied to Baskent University in Adana, Turkey. We see tremendous growth potential in Turkey and other international markets, and will continue our vigorous efforts to bring advanced radiosurgery and radiation therapy devices to additional partner hospitals in the United States and around the world." About Gamma Knife® PerfexionTM Gamma Knife Perfexion maintains full clinical compatibility with the classic Gamma Knife and is supported by efficacy and outcome data from 600,000 treated patients worldwide and thousands of peer-reviewed scientific articles, making it a proven choice for radiosurgery of the brain. According to its manufacturer, Elekta, Gamma Knife Perfexion reduces unwanted body dose to the patient by up to 100 times compared with competing technologies, which is particularly important for treatment of children and women of childbearing age, and allows for a dramatically increased treatable volume, which is expected to increase the number of patients that can benefit from Gamma Knife surgery. Elekta estimates that the fully automated and efficient single push-button approach can save 3-5 working weeks of physician time per year at an average Gamma Knife center. About AMS American Shared Hospital Services ( www.ashs.com) provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. Since 1991, AMS' creative financing solutions have enabled its clinical partners to make the latest advances in radiation oncology available to patients at an affordable price. AMS is the world leader in providing Gamma Knife® Radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st Century® concept. AMS also is a leader in proton beam radiation therapy (PBRT), the next great growth opportunity in radiation oncology. AMS currently is developing PBRT centers in Dayton, Ohio, Boston, Orlando and Long Beach, California, and is negotiating additional projects. AMS also owns a preferred stock investment in Mevion Medical Systems, developer of the compact MEVION S250 PBRT system, which has not yet been approved by the FDA. Safe Harbor StatementThis press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, and the risks of investing in a development-stage company, Mevion Medical Systems, Inc., without a proven product.Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 7, 2012.